Medtronic’s Evolut TAVR System Receives the US FDA’s Approval for Treating Aortic Stenosis
Shots:
- The US FDA has granted approval to Medtronic’s Evolut FX+ transcatheter aortic valve replacement (TAVR) system for treating symptomatic severe aortic stenosis patients at all risk categories incl. extreme, high, intermediate & low
- The Evolut FX+ TAVR system has a diamond-shaped frame design which increases coronary access windows providing greater catheter maneuverability required for accessing the coronary arteries across diverse patient anatomies
- The system’s early US commercialization is anticipated during spring 2024 with its full launch expected during summer 2024
Ref: Medtronic | Image: Medtronic
Related Post:- Medtronic Receives the US FDA’s Approval for its PulseSelect PFA System to Treat Atrial Fibrillation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
